Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

19.06.24 19:27 Uhr

Werte in diesem Artikel
Aktien

254,80 CHF 2,70 CHF 1,07%

Indizes

1.284,2 PKT 10,6 PKT 0,83%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

14.507,3 PKT 57,9 PKT 0,40%

2.002,6 PKT 14,3 PKT 0,72%

12.365,2 PKT 109,4 PKT 0,89%

1.691,2 PKT 13,2 PKT 0,79%

16.416,3 PKT 123,7 PKT 0,76%

3.765,8 PKT 25,3 PKT 0,68%

4.577,6 PKT 48,6 PKT 1,07%

16.278,1 PKT 122,5 PKT 0,76%

7.157,8 PKT 7,9 PKT 0,11%

Swiss pharma giant Roche Holdings RHHBY entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.Ascidian’s exon editing technology is designed to provide the durability of gene therapy by rewriting RNA, while sharply reducing the risks associated with direct DNA editing and gene replacement. This approach has the potential to treat patients with one dose of an RNA exon editor.Per the terms of the agreement, Roche will get exclusive, target-specific rights to Ascidian’s RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million. While Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, the latter will be responsible for certain preclinical activities and further clinical development, manufacturing and commercialization.In addition, Ascidian is eligible to receive up to $1.8 billion in research, clinical, and commercial milestone payments, as well as royalties on commercial sales worldwide. It also has the liberty to develop programs against other neurological targets internally or with other collaborators.Roche’s shares have lost 3.4% year to date against the industry’s growth of 20.4%.Image Source: Zacks Investment ResearchThe company is striving to expand its pipeline and diversify through strategic acquisitions and collaborations. In January 2024, Roche acquired a clinical-stage biotechnology company, Carmot Therapeutics, for $2.7 billion to foray into the lucrative obesity space.The acquisition gave Roche access to Carmot’s differentiated portfolio of incretins, including CT-388, the lead asset, phase-II ready, dual GLP-1/GIP receptor agonist for the treatment of obesity in patients with and without type 2 diabetes. Roche also obtained CT-996, a once-daily oral, small molecule GLP-1 receptor agonist currently in phase-I intended to treat obesity in patients with and without type 2 diabetes, and CT-868, a phase-II, once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist intended for the treatment of type 1 diabetes patients suffering from obesity.Roche also entered into a strategic collaboration and licensing agreement with MOMA Therapeutics in January. With this collaboration, Roche has access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival.Roche has also collaborated with MediLink Therapeutics for the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.Drugs like Vabysmo, Ocrevus, Hemlibra and Polivy fuel Roche’s top line as the company looks to fill up the dent in sales caused by a decline in COVID-19-related sales. Competition from biosimilars for established drugs like Avastin, MabThera/Rituxan and Herceptin continues to hurt sales. Approval of new drugs should bode well for Roche in this scenario.Zacks Rank & Stocks to ConsiderRoche currently carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND, ALX Oncology Holdings ALXO and Minerva Neurosciences, Inc. NERV, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.In the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share (EPS) has increased 15 cents to $4.71. During the same time frame, the consensus estimate for 2025 EPS has increased 70 cents to $5.90. Year to date, shares of LGND have risen 12.7%.Ligand beat on earnings in each of the trailing four quarters, delivering an average surprise of 56.02%.In the past 60 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73.ALX Oncology beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 8.83%.In the past 60 days, estimates for Minerva Neurosciences’ 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimate for 2025 has narrowed from $4.54 to $3.60 during the same time frame.NERV’s earnings beat estimates in one of the trailing four quarters and missed the same in the other three, the average negative surprise being 54.43%. Top 5 Dividend Stocks for Your RetirementZacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.See our Top 5 now – the report is FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report ALX Oncology Holdings Inc. (ALXO): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Roche

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Roche

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Roche AG (Genussschein)

Analysen zu Roche AG (Genussschein)

DatumRatingAnalyst
11.07.2024Roche UnderweightJP Morgan Chase & Co.
10.07.2024Roche HoldDeutsche Bank AG
10.07.2024Roche NeutralUBS AG
09.07.2024Roche NeutralUBS AG
05.07.2024Roche HoldDeutsche Bank AG
DatumRatingAnalyst
24.04.2024Roche KaufenDZ BANK
24.04.2024Roche OutperformBernstein Research
02.02.2024Roche KaufenDZ BANK
19.10.2023Roche KaufenDZ BANK
29.08.2023Roche BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
10.07.2024Roche HoldDeutsche Bank AG
10.07.2024Roche NeutralUBS AG
09.07.2024Roche NeutralUBS AG
05.07.2024Roche HoldDeutsche Bank AG
04.07.2024Roche NeutralUBS AG
DatumRatingAnalyst
11.07.2024Roche UnderweightJP Morgan Chase & Co.
05.07.2024Roche UnderweightJP Morgan Chase & Co.
04.07.2024Roche SellGoldman Sachs Group Inc.
04.07.2024Roche UnderweightJP Morgan Chase & Co.
02.07.2024Roche SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Roche AG (Genussschein) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"